The occurrence of both sporadic and NF2-associated vestibular schwannomas is associated with a loss of or a mutation in a tumor suppressor gene on chromosome 22q12 (1, 2) . The gene encodes the protein merlin or schwannomin, which normally accumulate under specialized regions of the cell membrane and functions as a membrane organizer and a linker of the cytoskeleton (3) . Merlins tumor suppressor function is likely to be linked to regulation of actin cytoskeleton-mediated processes and cell proliferation (reviewed in 4,5).
However, not all vestibular schwannomas exhibit inactivation of the merlin/schwannomin (4, 5) , and the phenotypical characteristics of those that do demonstrate a high degree of variability. Tumor growth rate and cyst formation are 2 clinically very important examples of variables concerning the phenotype.
In search of genes and pathways associated with vestibular schwannoma tumorigenesis, Welling et al. (6) used cDNA microarray analysis of tissue samples from 1 vestibular nerve versus 3 cystic sporadic, 3 solid sporadic, and 1 NF2-associated vestibular schwannoma. The human transcriptome was screened and a number of deregulated genes identified in tumor tissue, for example, upregulation of the angiogenesis mediators endoglin and osteonectin (SPARC), downregulation of the apoptosisrelated LUCA-15, and deregulation of the protein 4.1 superfamily members ezrin, radixin, and moesin, which are very similar to merlin. However, the limited number Copyright @ Otology & Neurotology, Inc. Unauthorized reproduction of this article is prohibited. of samples in this pioneering study was a disadvantage, which precluded meaningful statistical analyses. The present study examines the gene expression in tissue samples from 3 human vestibular nerves versus 16 solid, sporadic vestibular schwannomas using a microarray chip that quantitates the tissue content of individual mRNA molecules transcribed from the entire human genome, covering more than 20,000 genes. The aims were to identify deregulated genes and functional areas of potential importance for tumorigenesis to generate hypotheses and pinpoint potential areas of future research.
MATERIAL AND METHODS

Patient Data
Noncystic, solid, unilateral vestibular schwannoma tissue was sampled prospectively from 16 patients after translabyrinthine tumor excision. In 3 of the 16 cases, the tumor was excised en bloc with an intact and microscopically normal piece of the vestibulocochlear nerve attached, representing the part of the nerve located between the tumor and the brainstem. The microscopically normal piece of nerve was dissected meticulously from the tumor (to avoid contamination by tumor cells) and served as Bnormal[ control. Tumor sample and vestibular nerve tissue were snap-frozen immediately after tumor removal and stored at j80-C. Conventional microscopy of the remaining part of the tumor confirmed the diagnosis.
Debut symptom was hearing loss and/or tinnitus in all cases. The mean age at operation was 51.4 years (range, 26Y65 yr; standard deviation, 8.7). The male-to-female ratio was 1.67. Mean largest extrameatal tumor diameter at the last preoperative magnetic resonance scan was 17.9 mm (range, 13Y25 mm; standard deviation, 3.0).
Microarray Analysis
Total RNA was extracted using Trizol according to standard procedures. RNA (5 Kg) was used to synthesize doublestranded cDNA using Superscript Choice System (Invitrogen, Carlsbad, CA, USA) with an oligo-dT primer containing a T7 RNA polymerase promoter (GenSet). The cDNA was used as a template for in vitro transcription reaction to synthesize biotinlabeled antisense cRNA (BioArray high-yield RNA transcript labeling kit; Enzo Diagnostics, Farmingdale, NY, USA). After incubation at 94-C for 35 minutes in fragmentation buffer (40 mM Tris, 30 mM MgOAc, 10 mM KOAc), the labeled cRNA was hybridized for 16 hours to HG-U133A arrays (Affymetrix Inc., Santa Clara, CA, USA). The arrays were washed and stained with phycoerytrin conjugated streptavidin (SAPE) using the Affymetrix Fluidics Station 400 before the arrays were scanned in the Affymetrix GeneArray 2500 scanner, as described in the Affymetrix GeneChip protocol.
Microarray Data Analysis
The image files (cell files) were imported into the software package DNA-Chip Analyser (C. Li and W.H. Wong; http:// www.dchip.org) (7) . The array files were normalized using the multiarray invariant-set normalization method. The normalization was based on probes that have similar rank in the baseline and experiment array (invariant set). The invariant set was used to generate a piecewise linear median curve between the baseline probes and the experiment probes, which is used as the normalization curve (7) . Model-based expression indices were calculated using the PM/MM model implemented in dChip version 1.3.
Hierarchical clustering was done according to the algorithm in dChip version 1.3, with a distance measure of 1 minus the Pearson correlation coefficient applying the average linkage algorithm, with a p value threshold of 0.001 for significant sample clusters.
Differentially expressed genes were identified as differences between control and tumor tissue larger than 2-fold, with a conservative p value less than 0.000001 and a differences of means greater than 25.
The deregulated genes were matched against the established gene ontology (GO) database using the built-in annotation functionality in dChip, which is based on GO information from the Gene Ontology Consortium (8) .
Gene annotation enrichment analyses of the deregulated genes were performed against established GO clusters using the hypergeometric tests to assess overrepresentation (enrichment) of Gene Ontology categories.
For the number of genes in the deregulated gene list that are assigned to a given GO function, the hypergeometric p value was calculated for overrepresentation or underrepresentation of that particular function in the total number of deregulated genes as compared with the relative representation of that GO function in all annotated genes on the array.
RESULTS
A hierachial cluster of downregulated and upregulated probes/genes in tumor tissue is shown in Figure 1 , and the fold change of the individual probes/genes is displayed in Table 1 .
Only 3 transcripts encoding glycoprotein M6A, ribosomal protein S6 kinase, and vitelliform macular dystrophy 2 (bestrophin 1) were significantly downregulated using the previously described criteria.
Eighty-four probes were upregulated, corresponding to 75 different transcripts (Table 1) .
All deregulated transcripts were matched against established GO (8) , which revealed that 8 of the upregulated genes are involved in regulation of the cell cycle ( Fig. 2 ), 6 in cell morphogenesis (Fig. 3 ), 8 in cell development (Fig. 4 ), 11 in cell differentiation ( Fig. 5 ), 6 in cell death (Fig. 6 ), 13 in cell adhesion (Fig. 7) , 9 in extracellular matrix (Fig. 8) , and 50 in protein binding (not displayed; overlapping occurring).
Gene annotation enrichment analyses of the clustered genes showed significant enrichment of annotations for the extracellular matrix (p G 0.0002), cell adhesion ( p G 0.0001), and protein binding (p G 0.0004).
DISCUSSION AND CONCLUSION
Given the gene deregulation criteria of a 2-fold increase or decrease and a very conservative p value, we have identified 78 genes that were either upregulated or downregulated in vestibular schwannomas using adjacent vestibular nerve as control. The criteria were Copyright @ Otology & Neurotology, Inc. Unauthorized reproduction of this article is prohibited.
chosen after initial analyses using either more or less conservative cutoff values to provide an overview of gene expression and at the same time identify a reasonable number of genes on which to focus attention for further research. Thus, the enormous data set contains information on a number of other deregulated genes or pathways potentially involved in tumorigenesis that will appear if less conservative cutoffs are used. Furthermore, deregulated transcription is not necessarily a result of significance because posttranscriptional and posttranslational processing may modulate gene expression and and phenotype of the tumors. As indicated in Table 1 , a number of transcripts were upregulated more than 5-fold and 13 genes more than 10-fold. Several transcripts and their encoded proteins have putative functions of potential biologic relevance for vestibular schwannomas. When the factors were matched against established GO, it was found that 8 of the 75 upregulated genes are involved in regulation of the cell cycle, 6 in cell morphogenesis, 8 in cell development, 11 in cell differentiation, 6 in cell death, 13 in cell adhesion, 9 in extracellular matrix, and 50 in protein binding (overlapping occurring; Figs. 2Y8).
Additional analyses of the clustered transcripts showed significant enrichment of annotations for the extracellular matrix, cell adhesion, and protein binding. This is intriguing because mosaic NF2 (merlin) mutants exhibit a global defect in tissue fusion characterized by ectopic detachment and increased detachment-induced apoptosis in the transgenic study of neuroprogenitors by McLaughlin et al. (9) . This indicates that regulation of NF2 expression is a means of controlling cellular adhesion between Schwann cells, and between Schwann cells and axons within the vestibular nerve, which is in agreement with merlin-associated CD44 implication in cell-cell adhesion, cell-matrix adhesion, and tumor progression (10, 11) , as well as the fact that merlin colocalizes and interacts with adherence components in confluent cells (12) . Furthermore, fibroblasts lacking NF2 function do not undergo contact-dependent growth inhibition and cannot form stable cadherin-containing cell/cell junctions, which shows that merlin functions as a tumor suppressor by controlling cadherin-mediated cell/cell contact (12) . It has also been suggested that merlin mediates contact inhibition of cell growth through signals from the extracellular matrix (13) . Thus, the enrichment of gene annotations for the extracellular matrix, cell adhesion, and protein binding in tumor tissue may be an indication of upregulation in response to effects of downregulated or dysfunctional merlin. Accordingly, these functional areas may be important for the development of a vestibular schwannoma and constitute obvious fields of future research.
We found no deregulation of the merlin/schwannomin gene (downregulation expected), again given the previously described conservative criteria. We did, however, find an upregulation of the 4.1-band ezrin-radixin-moesin (FERM) domain (containing 4A; 6.7-fold) and of erythrocyte membrane protein band 4.1 (13-fold). Merlin/schwannomin is very similar to the protein 4.1 superfamily members (including ezrin-radixin-moesin and erythrocyte membrane protein band 4.1) linking the molecules to functions related to the cell membrane and cytoskeleton. The FERM domain is an N-terminal globular domain that occurs in all members of the family and has been suggested to contain key functional domains for merlin.
Radixin and moesin was upregulated, whereas ezrin was downregulated in the study by Welling et al. (6) . As the protein 4.1 superfamily members, RhoB is also involved in organizing the cytoskeleton, and both studies showed an upregulation of RhoB GTPase (activating protein 15; Table 1 ). Thus, factors with functional relation to merlin/ schwannomin seem to be potentially involved in tumor development. When addressing potential merlin deregulation, it is important to note that the adjacent vestibular nerve control tissue could have a single merlin mutation or loss of heterozygosity, which may explain the lack of a finding of downregulated merlin in tumor tissue. In addition, the protein product may be nonfunctional or dysfunctional in tumor tissue, although transcription and translation are normal, as also previously addressed in general terms.
Apart from the enriched annotations, a number of specific genes are relevant candidates for further research (Table 1) . A complete account of the functions of these genes would be too exhaustive for the scope of this article. However, 1 example is platelet-derived growth factor D, which apart from being a growth factor is involved in the cell cycle (Fig. 2) and upregulated more than 54-fold in tumor tissue. Platelet-derived growth factor D is active in the development of the brain and plays a role in glioblastomas/medulloblastomas, as well as other types of cancer (14) . Conceivably, growth factors will be involved during growth of the tumor after the initial cellular events leading to its formation and apart from platelet-derived growth factor D, a number of other growth factors or growth factor-associated genes were upregulated in tumor tissue: growth factor receptor-bound protein 14, insulin-like growth factor binding protein 4, and transforming growth factorYA receptor II (Table 1) . Transforming growth factorYA plays an essential role in Schwann cell proliferation and differentiation, and is involved in neurotrophic effects of several neurotrophic substances. The expression of the growth factor and its receptors I and II in vestibular schwannomas has been evidenced by immunohistochemistry and RT-PCR (15) .
Another interesting upregulated gene is PTEN (phosphatase and tensin homolog deleted on chromosome 10), which is involved in the cell cycle, in cell development, differentiation, and adhesion, as well as apoptosis (Figs. 2, 4Y7 ). Apart from being involved in the differentiation of gliomas (16), PTEN is the major negative regulator of the growth promoting phosphatidylinositol 3-kinase/AKT pathway, which is activated in vestibular schwannomas, possibly due to lack of merlin inhibition (17) . Two other genes with potential relation to the PI3K/AKT pathway were also upregulated: inositol 1,4,5-triphosphate receptor type 1 and WD40 repeat protein interacting with phosphoinositides (Table 1) . Phosphoinositides has the potential to convert merlin from the closed to the open conformation, which is essential for function (reviewed in 4).
Welling et al. (6) examined vestibular schwannoma gene expression using the same technology as presently employed. They identified 42 genes upregulated more than 3-fold, whereas 8 genes involved in cell growth and signaling were downregulated. When comparing their data to ours, 4 identical or closely associated genes were upregulated in both studies: Rho GTPase activating protein 15, S100 calcium-binding protein A11 (calgizzarin), fibronectin leucine-rich transmembrane protein 3, and actinrelated protein 2/3 complex (Table 1) .
Another interesting comparison between the studies is related to the upregulation of osteonectin (SPARC) found by Welling et al. SPARC interacts with extracellular matrix proteins (enriched annotation in our study) and acts as a mediator of angiogenesis. Our results showed an upregulation of the scavenger receptor stabilin 1 (12-fold), which mediates targeting for degradation of SPARC (18) .
Although equivalent platforms were used, several reasons may explain the limited degree of accordance between the 2 studies such as differences of material and data set analyses (see preceding sentences). Thus, the pioneering study by Welling et al. included a limited number of 7 heterogenic tumor samples (3 sporadic, 3 cystic, and 1 NF2 tumor) and one control (vestibular nerve), which precluded meaningful statistical analyses. We sampled a homogenic material, including 16 sporadic (unilateral, noncystic) tumors and 3 vestibular nerves as control, the latter being the lower limit for statistical analyses. The sampling of more tumors and especially more control tissue will strengthen the validity of future results from our material.
Lasak et al. ( Welling and Chang's group) (19) studied the deregulation of the pRb-CDK pathway in 8 vestibular schwannomas (4 sporadic, 3 cystic, and 1 NF2 tumor) using the same chip and 1 vestibular nerve as control. As the only deregulated gene, CDK2 was underexpressed, which was confirmed by RT-PCR and immunohistochemistry. Conflictingly, our analysis revealed an upregulation of CK2 (mean, 5-fold).
Cyclin D1 is involved in the cell cycle ( Fig. 1 ) and in the pRb-CDK pathway and was found to be upregulated 7-fold in our material (Table 1) Neuregulin-epidermal growth factor receptor (NrgErb) signaling contributes to vestibular schwannoma proliferation (22, 23) and has accordingly been suggested as a potential target for pharmacotherapy (24) . The expression of genes associated with Nrg-Erb signaling has been quantitated by quantitative PCR, which showed an upregulation of neuregulin, epidermal growth factor receptor, and ErbB2 in most sporadic tumors, using vestibular, sciatic, and greater auricular nerve as control (24) . None of a number of genes associated with Nrg-Erb signaling was presently deregulated, again given the previously defined analysis criteria.
Only 3 genes were found to be downregulated in tumor tissue: glycoprotein M6A, ribosomal protein S6 kinase, and vitelliform macular dystrophy 2 (bestrophin 1).
